Pricing Log in Create free account
Friday 6 November 2026 Export PRPH’s income statement to Excel — free account

ProPhase Labs, Inc.

PRPH Healthcare Diagnostics & Research

ProPhase Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 35.8% from fiscal 2024.

Revenue
−18.9%
EPS
+80.0%
Free cash flow
+56.7%
Total debt
+19.4%

Quarter to June 2026, against a year earlier

0.01 0.00 0.00%
Market cap
$1.2M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
4/9
Altman Z
−3.59
Beneish M
−4.90
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 60.12%

Capital & Financial Ratios $m

Size
Market Cap 1.17
Revenue ttm 3.16
Net income ttm (22.46)
Free cash flow ttm (5.53)
Net debt Q 5.65
Valuation
P/E 0.00
Forward P/E (0.63) (negative: loss-making)
Price / sales 0.04
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.05 (below 1: weak)
Debt / equity Q (1.82) (negative: negative equity)
Interest coverage Q (3.34)
Growth
Revenue growth Q −18.93% (below 0%: shrinking)
Operating income growth Q +32.07% (above 0%: growing)
EPS, this year +78.54% (at or above 15%: strong)
EPS, next year A +55.91% (at or above 15%: strong)
Revenue, next year A +859.49% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.8×, against a ten-year median of 1.9×; over the ten years it ranged from −10.4× in 2016 to 9.7× in 2020.
P/S against its own 10 years 1.42%
10-year low 10-year high
EV/Sales against its own 10 years 36.23%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 5 1 0 0
Receivables 36 20 2 2
Inventory 2 1 0 0
Other 3 6 — —
48 31 3 3
2023 2024 2025 Q'26
Payables 9 14 41 43
ST’ Debt — 3 5 6
Other 3 2 3 3
21 32 53 58

Compound Annual Growth %

10y 5y 3y
Sales 5.61% (21.43%) (67.16%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (8.82%) (19.77%) (61.94%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY25 Estimate −1.50 Actual −1.10

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY24 −0.80 −3.30 Miss by 2.50
Q3 FY24 −3.10 −3.50 Miss by 0.40
Q1 FY25 −1.80 −1.20 Beat by 0.60
Q2 FY25 −1.50 −1.10 Beat by 0.40

EPS $

Mar Jun Sep Dec Year
’26 (0.43) (0.22) — — —
’25 1.10 (1.10) (1.60) (0.33) (1.74)
’24 (3.64) (3.30) (3.50) (16.33) (26.10)
’23 0.30 (2.00) (3.00) (5.10) (9.80)
’22 6.80 4.00 0.48 (1.11) 10.20
’21 0.60 (0.90) (2.60) 6.80 4.00
’20 (0.70) 0.06 (0.40) (0.84) (1.80)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 1 — — —
’25 1 1 1 1 4
’24 2 2 1 1 7
’23 19 13 8 3 35
’22 48 29 24 22 123
’21 15 9 9 45 79
’20 2 4 4 5 15
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 0 — — —
’25 (3) 0 (3) (1) (8)
’24 (5) (5) (4) (4) (18)
’23 0 (7) (5) (1) (12)
’22 20 5 3 1 29
’21 (8) 4 (6) (5) (14)
’20 0 4 0 (7) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 0 — — —
’25 (3) 0 (3) (1) (8)
’24 (6) (5) (4) (4) (18)
’23 (3) (8) (5) 2 (14)
’22 19 4 2 (1) 25
’21 (12) 4 (15) (5) (27)
’20 0 4 (1) (6) (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 4 10 13 10 15 79 123 35 7 4 3 +0.4% 42 — — +859.5%
Gross margin, % 23.70 19.74 36.42 26.48 31.73 53.12 57.61 44.47 (2.22) 31.85 16.38 +8.2 pt
EBT (4) (4) (1) (3) (2) 5 23 (22) (42) (23) (22) +21.7%
EBT margin, % (95.24) (37.12) (11.18) (31.45) (15.94) 6.71 18.68 (64.02) (625.26) (538.25) (698.19) (443.0) pt
Net income (3) 41 (2) (3) (2) 6 18 (17) (53) (15) (22) +20.0%
Per share, $
Per share, $ Revenue 2.46 6.34 11.52 8.54 12.52 52.10 77.40 20.33 3.39 0.51 0.23 (16.0%)
Earnings (1.70) 26.90 (1.50) (2.70) (1.80) 4.10 11.70 (9.80) (26.10) (1.74) (2.58) +0.3%
Cash flow (0.28) (1.82) (1.86) (0.73) (2.24) (8.98) 18.02 (6.91) (8.77) (0.98) (0.40) +15.1%
Capex (0.38) (0.13) (0.12) (0.20) 0.34 (8.76) (2.19) (1.18) (0.34) 0.01 0.00 n/m
Free cash flow (0.66) (1.96) (1.98) (0.92) (1.90) (17.74) 15.83 (8.09) (9.11) (0.97) (0.39) +4.4%
Book value 3.49 20.46 14.48 9.71 9.10 38.64 40.16 28.70 3.68 0.41 (0.22) (21.1%)
Shares, m 2 2 1 1 1 2 2 2 2 8 13 +19.5%
Valuation, ×
Valuation, × P/E 0.00 0.85 0.00 0.00 0.00 17.93 7.98 0.00 0.00 0.00 0.00 2.7
P/S 8.24 3.53 2.73 2.31 7.33 1.38 1.24 1.80 2.24 2.29 0.04 3.3
P/B 5.82 1.09 2.18 2.03 10.08 1.86 2.38 1.62 2.06 2.84 0.00 3.2
EV/Sales 8.84 1.61 2.33 2.47 7.46 1.29 1.12 2.01 4.71 3.60 1.84 3.5
EV/FCF (33.12) (5.22) (0.71) (22.81) (49.23) (3.79) 5.46 (6.41) (1.75) (1.90) (1.05) (11.9)
Cash, $m
Cash, $m Operating cash flow 0 (3) (2) (1) (3) (14) 29 (12) (18) (8) (6) +37.6%
Capex (1) 0 0 0 0 (13) (3) (2) (1) 0 0 n/m
Free cash flow (1) (3) (2) (1) (2) (27) 25 (14) (18) (8) (6) +24.8%
Balance, $m
Balance, $m Working capital 3 27 14 9 10 46 45 27 (1) (50) (55) n/m
Net debt 1 (22) (8) (1) 2 (7) (15) 7 17 6 6 +20.7%
Shareholders’ equity 6 32 17 11 11 59 64 49 7 4 (3) (5.7%)
Returns, %
Returns, % ROA (20.76) 174.72 (6.40) (19.06) (9.73) 10.39 20.87 (18.69) (68.80) (23.96) (45.53) (3.2) pt
ROIC (33.82) (25.17) (12.36) (20.51) (10.47) 11.82 30.16 (23.65) (100.08) (122.44) (387.30) (88.6) pt
ROE (38.78) 214.71 (7.20) (22.69) (19.51) 18.13 30.20 (29.70) (188.11) (271.49) (543.95) (232.7) pt
People
People Employees 53 46 50 50 95 129 129 113 96 19 — (10.8%)
Revenue/emp, $m 0.08 0.21 0.26 0.20 0.15 0.61 0.95 0.31 0.07 0.23 — +12.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

ProPhase Labs, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NDRA ENDRA Life Sciences Inc. $7.5M — (loss-making) — (loss-making) −98.80% (below 0%: shrinking) n/m +15.04% (above 0%: growing) 0.00% 0.00% Compare
TTOO T2 Biosystems, Inc. $6.5M — (loss-making) — (loss-making) +34.85% (above 0%: growing) n/m +53.36% (above 0%: growing) (106.60%) (511.89%) Compare
XWEL XWELL, Inc. $6.1M — (loss-making) — (loss-making) −7.08% (below 0%: shrinking) n/m −43.02% (below 0%: shrinking) 41.26% (29.45%) Compare
BIAF bioAffinity Technologies, Inc. $3.3M — (loss-making) — (loss-making) +18.99% (above 0%: growing) n/m −23.69% (below 0%: shrinking) 27.98% (220.77%) Compare
DMTKQ DermTech, Inc. $3.3M — (loss-making) — (loss-making) +10.58% (above 0%: growing) n/m +24.87% (above 0%: growing) 18.54% (533.37%) Compare
ADVB Advanced Biomed Inc. $3.1M 0.3× — — n/m −101.33% (below 0%: shrinking) — 0.00% Compare
AWHL Aspira Women's Health Inc. $2.4M — (loss-making) — (loss-making) −14.89% (below 0%: shrinking) n/m −24.57% (below 0%: shrinking) 55.28% (89.69%) Compare
ISPC iSpecimen Inc. $2.0M — (loss-making) — (loss-making) −78.70% (below 0%: shrinking) n/m −257.73% (below 0%: shrinking) 45.23% (897.30%) Compare
PRPH ProPhase Labs, Inc. $1.2M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 22.35% (261.62%)
Median of peers $3.3M — — −7.08% — −24.13% 27.98% (155.23%)

All 49 Diagnostics & Research stocks →

ProPhase Labs, Inc. (PRPH) Latest News

15 Apr

Impact 4 ·

17 Mar

Impact 3 · · GlobeNewswire

3 Feb

Impact 4 · · GlobeNewswire

2 Feb

Impact 3 · · GlobeNewswire

26 Jan

Impact 4 · · GlobeNewswire

22 Jan

Impact 4 · · GlobeNewswireSimply Wall St.Insider MonkeyBarchartMT NewswiresSimply Wall St.Simply Wall St.Simply Wall St.

5 Jan

Impact 3 · · GlobeNewswireMT NewswiresMT NewswiresSimply Wall St.Simply Wall St.

19 Dec

Impact 4 ·
Impact 4 · · GlobeNewswireGuruFocus.comMT NewswiresMT NewswiresMedical Device NetworkInsider MonkeyInsider MonkeyMT Newswires
Impact 4 · · Business WireGuruFocus.comMT NewswiresMT NewswiresMedical Device NetworkMT NewswiresInsider MonkeyMT Newswires
Impact 3 ·

26 Nov

Impact 4 · · GuruFocus.comGuruFocus.comGuruFocus.com transcript
Impact 3 · · GlobeNewswire

20 Nov

Impact 4 · · Moby

29 Oct

Impact 4 · · GlobeNewswire

28 Oct

Impact 3 · · GlobeNewswire

24 Oct

Impact 3 · · GlobeNewswire

22 Oct

Impact 4 · · GlobeNewswire

23 Sep

Impact 4 · · TheStreet
Impact 4 · · GlobeNewswire

12 Sep

Impact 3 · · Associated Press Finance

15 Aug

Impact 4 · · GuruFocus.com transcript

12 Aug

Impact 4 ·
Impact 3 ·

29 Jul

Impact 3 · · GlobeNewswire

26 Jun

Impact 3 ·

17 Jun

Impact 4 · · GlobeNewswire

6 Jun

Impact 4 ·

21 May

Impact 3 · · GuruFocus.com

20 May

Impact 4 · · GlobeNewswire
stockrow.com/PRPH · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com